Symbols

AXDX(Delisted)

Accelerate·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 1

EPS Beats Expectation

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About AXDX

Accelerate Diagnostics, Inc.

A developer of culture-free analysis and medical diagnostic products for rapid bacterial identification

Industry

Established Date

05/26/1982

Listing Date

12/26/2012

Exchange

NASDAQ Stock Exchange

Full-time Employees

107

Fiscal Year Ends

12-31

Website

acceleratediagnostics.com

Security Type

Common stock

Office address

3950 South Country Club Road, Suite 470, Tucson, AZ 85714

Business

Introduction

Accelerate Diagnostics, Inc., was established on May 26, 1982 as a Delaware corporation. The company is an in vitro diagnostic company dedicated to providing solutions to improve patient prognosis and reduce healthcare costs through rapid diagnosis of serious infections.

Company Financials

EPS

AXDX has released its 2023 Q3 earnings. EPS was reported at -1.18, versus the expected -1.07, missing expectations. The chart below visualizes how AXDX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

AXDX has released its 2024 Q4 earnings report, with revenue of 2.82M, reflecting a YoY change of -6.97%, and net profit of -9.59M, showing a YoY change of 26.23%. The Sankey diagram below clearly presents AXDX's revenue sources and cost distribution.